Bullet Blockchain Inc (BULT): Bullet Blockchain Inc. is a multifaceted...

Play Episode

6min

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Proactive - Interviews for investors

North Bay Resources announces first gold concentrate sale from Fran Gold Project

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to share news of the company’s first successful gold concentrate sale from a test shipment processed at the Bishop Gold Mill, using ore from the Fran Gold Project. Lazerson confirmed that final acceptance and settlement have been completed, with all refinery requirements met, and assay comparisons for gold, silver, and moisture content agreed upon. The test concentrate represents approximately 10 tons of gross ore, processed through the gravity-only circuit. Lazerson noted this marks an important milestone in the early phase of operations. The flotation circuit, which is expected to significantly enhance recovery rates, is set to come online this month. The company currently has another test shipment in process and has completed a third concentrate shipment, further validating operational momentum. The most recent sale netted approximately $400 per ton, based solely on gravity recovery. However, with further optimization and the integration of the flotation circuit, recoveries are projected to double, potentially reaching over 90% total recovery. This would raise the value per ton to around $800, significantly improving project economics. North Bay Resources currently has 75 tons of ore stockpiled at the Bishop Gold Mill, which will be processed as part of continued optimization and ramp-up. Additionally, there are approximately 5,000 tons of ore stockpiled at the project site, positioning the company for a steady flow of future shipments as operations scale. The CEO also discussed the reinterpretation of 15 years of historical drilling data—104 holes covering 18,000 metres—which has revealed the potential for a bulk tonnage deposit. This reinterpretation aligns with nearby major low-grade, high-volume gold projects like Mount Milligan and Blackwater. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #G

Proactive - Interviews for investors

FDA approval sees Orthocell’s Remplir enter multi-billion dollar US nerve market

Orthocell Ltd chairman John van der Wielen talked with Proactive about the company receiving FDA clearance for its nerve repair product, Remplir, paving the way for entry into the multi-billion US healthcare market. The approval marks a significant milestone in Orthocell’s international growth strategy and reflects the strength of its regulatory and clinical capabilities. Van der Wielen emphasised the significance of breaking into the US market in a challenging regulatory environment. “Not many people would have thought with the current US turmoil, a company like ours could achieve FDA clearance,” he said. Orthocell has established operations in the US with logistics and distribution already in place. The company is implementing a hybrid sales model using in-house personnel and regional distributors, aiming for rapid initial uptake with an eye on more exclusive arrangements in the future. Remplir’s three-year shelf life and no temperature control requirement make it ideal for streamlined deployment. He also highlighted that Orthocell has already performed over 2,000 procedures in Australia and anticipates the US market to be 20 to 30 times larger, creating a strong revenue opportunity. With $32 million in cash reserves, the company expects to become cash flow positive within two years. 👉 For more interviews and updates, head to Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications. #Orthocell #FDAApproval #Remplir #NerveRepair #MedicalDevices #BiotechNews #USHealthcare #OrthocellRemplir #InvestorUpdate #ProactiveInvestors #SurgicalInnovation #ASX

Proactive - Interviews for investors

North Bay Resources identifies potential of major gold deposit at Fran Project

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to announce the discovery of a significant mass tonnage gold deposit at the Fran Gold Project, following an extensive review of prior exploration work. This includes data from diamond drilling campaigns between 2001 and 2018, as well as geochemical, geophysical, and 3D modeling analyses. Key findings reveal that past drilling—totaling over 18,000 meters—intersected large gold-bearing zones, with notable intercepts of up to 149 meters (489 feet) at 0.95 grams per tonne (g/t) gold. The identified deposit spans over 1,000m x 100m x 300m within a known strike length of 1,700m, indicating an exploration potential of 79.5 million tonnes, with an average grade of 0.8 g/t gold, translating to a potential 2 million ounces. Lazerson stated that there is now sufficient data to proceed with a NI 43-101 Compliant Mineral Resource Estimate. Historically, exploration at Fran focused on high-grade vein targets for underground mining, leaving the bulk tonnage potential largely unexplored. However, North Bay's latest review has shifted its strategy, incorporating both high-grade surface material for processing at its Bishop Gold Mill and ongoing evaluation of the mass tonnage gold deposit for future large-scale mining opportunities. This dual approach could significantly enhance North Bay’s production capacity, reinforcing its commitment to maximizing the Fran Gold Project’s full economic potential #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #MiningUpdates ---#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Followers	13
Posts	884
Boards Moderated	0
Alias Born	03/11/2021

Volume:	27,876
Day Range:	0.0431 - 0.047325
Bid:	0.0431
Ask:	0.06
Last Trade Time:	12:31:02 PM EDT
Total Trades:	4

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BULT Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free